Arcutis Biotherapeutics, Inc. Income Statement

Income Statement Dec2018 Dec2019 Dec2020 Dec2021 Dec2022 Dec2023 Dec2024
Revenue & cost
Revenue 3.69M59.61M196.54M
Cost of Revenue 0.75M4.99M19.13M
Gross Profit 2.93M54.62M177.41M
Operating items
Research & Development 115.31M145.56M182.44M110.58M76.42M
Selling, General & Administrative 21.34M60.97M122.12M185.15M229.39M
Other Operating Expenses 0.75M4.99M19.13M
Operating Expenses 136.65M206.53M305.31M300.71M324.94M
Operating Income -136.65M-206.53M-301.63M-241.10M-128.40M
EBIT -136.65M-206.53M-301.63M-241.10M-128.40M
Non-operating items
Other Non Operating Income 0.97M0.17M5.82M11.79M16.17M
Non Operating Income 0.97M0.17M5.82M11.79M16.17M
Net income details
EBT -136.65M-206.36M-311.46M-259.03M-139.39M
Tax Provisions 3.11M0.65M
Profit After Tax -135.68M-206.36M-311.46M-262.14M-140.04M
Income from Continuing Operations -136.65M-206.36M-311.46M-262.14M-140.04M
Consolidated Net Income -136.65M-206.36M-311.46M-262.14M-140.04M
Income towards Parent Company -136.65M-206.36M-311.46M-262.14M-140.04M
Net Income towards Common Stockholders -136.65M-206.36M-311.46M-262.14M-140.04M
Additional items
EPS (Basic) -0.00M-0.00M-0.00M-0.00M-0.00M
EPS (Weighted Average and Diluted) -0.00M-0.00M-0.00M-0.00M-0.00M
Shares Outstanding (Weighted Average) 35.06M38.09M50.08M50.30M60.93M94.38M118.64M
Shares Outstanding (Diluted Average) 35.67M49.41M55.03M69.31M120.96M
EBITDA -135.68M-206.61M-312.29M-261.05M-140.05M